Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esmolol in severe acute pancreatitis with tachyarrhythmia
ChiCTR2000039721Phase 4Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Nov 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of esmolol in acute pancreatitis (AP) and tachyarrhythmia (2 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoint: All-cause mortality at 30 days. Started Nov 2020; status: recruiting.
02
Drugs
esmolol
03
Conditions
acute pancreatitis (AP)tachyarrhythmia
Beyond the preview
Go deeper on ChiCTR2000039721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039721.